05:10 PM EST, 11/18/2024 (MT Newswires) -- GRAIL (GRAL) said Monday the first patient has been tested for eligibility with the company's investigational lung cancer ctDNA blood-based test in a phase 3 trial assessing adjuvant treatment regimens in people with non-small cell lung cancer.

The trial, which is sponsored by AstraZeneca ( AZN ) in collaboration with Daiichi Sankyo, uses GRAIL's targeted methylation platform to detect ctDNA, GRAIL said.

People will be screened with the GRAIL assay before surgery to assess eligibility for post-surgery randomization to an adjuvant treatment regimen, the company said.

Price: 15.53, Change: -0.39, Percent Change: -2.45